Slide background
Slide background
Slide background
Slide background

Welcome to TropMed Pharma Consulting

TropMed Pharma Consulting specialises in advising companies, academic institutions, non-governmental organisations (NGOs), and governmental and intergovernmental organisations working on malaria and neglected tropical diseases to help them be more successful.

The challenges in this field are often different from those faced by projects in other areas of medicine. Most projects in this area are carried out in the form of public-private partnerships (PPPs) or product development partnerships (PDPs). The involvement of many different parties from the public and private spheres, with different objectives, skill sets, and expertise can raise challenges that have often not been experienced before by the organisations involved.

Ian Boulton (Managing Director) brings more than 30 years experience in the pharmaceutical industry and over 15 years working in this field to meeting TropMed Pharma Consulting’s Mission. He has been involved in many public-private partnerships and so has experiences (good and bad) to draw on and inform the advice to our clients.

Mission Statement

TropMed Pharma Consulting specialises in advising companies, academic institutions, non-governmental organisations (NGOs), and governmental and intergovernmental organisations working on malaria and neglected tropical diseases to help them be more successful.

About our work

meetingPlanning, R & D, building partnerships and encouraging best practice are key to our success. We work closely with pharmaceutical companies, private and public sector organisations to develop robust strategies in the discovery, development, and deployment of new drugs.

Our expertise

scientistsIan Boulton has over 30 years' experience working in the pharmaceutical industry, R&D, sales, marketing, business development, strategic planning, & general management. He is recognised as a leading figure in the global effort to control, eliminate, and ultimately eradicate malaria and other tropical diseases.

Client Recommendations

Steven C Phillips

I worked directly with Ian as private sector representative on the Board of Roll Back Malaria. Ian is very knowledgeable about business sector issues relating to neglected diseases, ranging from manufacturing to distribution, marketing and sales. He is an excellent communicator and strategist, and works well building coalitions within and across sectors. It was a privilege to work with him over 4 years. (October 26, 2008)

Senior Fellow, Chatham House: formerly Medical Director - Global Issues and Projects, Exxon Mobil Corporation

Matt Lynch

Ian is a valued and highly-professional consultant and colleague. He worked very hard under a tight timeline and politically charged atmosphere to deliver an extremely well-written and useful document for the Executive Committee of the RBM Board.. This provided the background needed to develop consensus and move a potentially divisive issue towards resolution. Ian has served with me on the RBM Board, and is a strong contributor to the success of the Private Sector Delegation on that Board. (January 23, 2013)

Director of Global Program on Malaria, Center for Communication Programs, Bloomberg School of Public Health, Johns Hopkins University

Prof Trevor Jones

Ian is one of the leading world experts on Drug Discovery, Development, and Accessibility of Medicines for the Developing World. His expertise across a wide range of infectious diseases that primarily afflict patients in the Developing World is broad-based - ranging from drug design,through clinical development and delivery, to healthcare systems.He has been singularly helpful in advising international organisations and pharmaceutical companies in this field. (January 11, 2013)

President, Sigma Tau Pharmaceuticals Inc.: formerly Director-General, ABPI; Director of R&D, Wellcome Foundation

Alan Court

I have known Ian for several years, working with him and also sitting on the same Board and in different working groups and task forces of the Roll Back Malaria Board. He is an outstanding colleague who has a capacity to turn multiple and diverse pieces of information into a coherent plan or recommendation having carefully validated with all stakeholders. He is a first-rate analyst who is able to put together plans and budgets as well as set up systems, giving him a diverse capacity useful for any organization whether a start-up, under reorganization or evaluation. This is in addition to his own area of pharmaceuticals where he is also a valuable asset. Ian also writes well, clearly and concisely. A wonderful colleague and a thorough professional. (27 September 2010)

Senior Advisor - UN Secretary General’s Special Envoy for Malaria

Prof Steve Ward

I first worked with Ian when he was with GlaxoSmithKline and representing them in a public-private partnership aimed at developing & delivering affordable and safe antimalarial drugs. What was most striking at the time was Ian's immediate grasp of the most relevant scientific issues we had to deal with, his eye for the problems that might blight our progress, and his professional and pragmatic approach to overcoming these difficulties. It was these qualities and his excellent facilitating skills that convinced me to ask Ian to work with us on an important EU-funded consortium focused on setting the antimalarial drug R&D agenda for the next decade. The success of this project has in large part been down to Ian's ability to identify key opinion leaders and co-ordinate, convene, and facilitate a complex series of meetings and workshops. Ian has managed to engage quite senior academics in innovative "brain-storming" sessions in order to get a fresh view on the issues and the potential ways forward. This has been stimulating, engaging, and - most importantly - highly effective. (April 23, 2010).

Deputy Director, Liverpool School of Tropical Medicine

David Brandling-Bennett

During my 10 years with the Bill and Melinda Gates Foundation, I have had multiple opportunities to work with Ian, especially since joining the RBM Board in 2008.  Both as a RBM Board member himself and subsequently as a consultant, Ian has brought the rigorous thinking and experience of the private sector to a largely public sector oriented partnership.  His knowledge of market dynamics and the vital but often poorly understood role of the private sector was critical to the success of the Affordable Medicines Facility for Malaria (AMFm), which showed clearly that access through the private sector to quality affordable antimalarial drugs could be increased significantly.  With his knowledge and experience in the full range of drug discovery, development, and delivery, Ian can provide essential support to all those seeking to improve access by under-served populations to life-saving commodities, especially by using his skills working with both the private and public sectors. (26 June 2014)

Senior Advisor - Malaria, Global Health Division, Bill & Melinda Gates Foundation